Get In Touch

Xilio Therapeutics is a biotechnology company that uses its proprietary technology to develop next-generation cancer immunotherapies.

For investor inquiries: investors@xiliotx.com

For media inquiries: xiliotxmedia@jpa.com

Xilio News

06/17/2021
Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors

Xilio Therapeutics

Read more >

06/08/2021
Xilio Therapeutics XTX202 (IL-2) Poster Presentation at ASCO

Xilio Therapeutics

Read more >

05/25/2021
Xilio Therapeutics Announces Clinical Trial Collaboration with Merck on AntiCTLA-4 Monoclonal Antibody Program

Xilio Therapeutics

Read more >

05/20/2021
Xilio Therapeutics to Present Preclinical Data Highlighting Anti-Tumor Activity and Tolerability of XTX202 at the 2021 ASCO Annual Meeting

Xilio Therapeutics

Read more >

05/13/2021
Xilio Therapeutics XTX101 (CTLA-4) Poster Presentation at NYAS

Read more >

05/12/2021
Xilio Therapeutics Presents Preclinical Tumor-Selective Activity and Tolerability Data for XTX101 at Frontiers in Cancer Immunotherapy Virtual Symposium

Read more >

05/05/2021
Xilio Therapeutics Appoints Christina Rossi to its Board of Directors

Read more >

04/12/2021
Xilio Therapeutics Strengthens Management Team with R&D Leadership Appointments

Read more >

03/29/2021
Xilio Therapeutics Strengthens Leadership Team with the Addition of Two Executives

Read more >

02/24/2021
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

Read more >

11/13/2020
Xilio Therapeutics XTX101 (CTLA-4) Poster Presentation at SITC

Read more >

11/12/2020
Xilio Therapeutics XTX201 (IL-2) Poster Presentation at SITC

Read more >

11/12/2020
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC

Read more >

11/10/2020
Xilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Read more >

11/06/2020
Xilio Therapeutics Appoints Rachel Humphrey, M.D. to Board of Directors

Read more >

07/23/2020
Xilio Therapeutics Appoints Paul J. Clancy to its Board of Directors

Read more >

06/17/2020
Xilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors

Read more >

04/27/2020
Xilio Therapeutics Appoints Martin H. Huber, M.D. as Chief Medical Officer

Read more >

03/02/2020
Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing

Read more >

06/12/2019
Akrevia Therapeutics Appoints Joseph Farmer as Chief Operating Officer

Read more >

05/22/2019
Akrevia Therapeutics Appoints ReneĢ Russo, PharmD, as Chief Executive Officer

Read more >

05/16/2019
Akrevia Therapeutics Appoints Distinguished Research Leaders to Scientific Advisory Board

Read more >

03/16/2019
Akrevia Therapeutics Licenses Exclusive Rights from City of Hope to Expand Development Pipeline of Potent, Tumor Targeted Immunotherapies

Read more >

09/27/2018
Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture

Read more >


Read more >